Gastroenterology

Currently, DAAs lack FDA approval for hepatitis C treatment in children under 12 years, but pediatricians call for their approval.

A randomized trial compared cash incentives, peer support, and usual care for increasing rate of HCV treatment among HCV/HIV infected people who use drugs.

A new study of 55 million insured young adults in the US found that major depression, type 2 diabetes, and other conditions are becoming more prevalent among them.

A study of DAA treatment of HCV in the US finds high adherence and effectiveness at less cost than when the antivirals were introduced.

Investigators identified reasons veterans might decline or not adhere to HCV treatment and proposed ways to optimize treatment.

A small study in Colorado reported that regular marijuana users require significantly greater amounts of sedatives for endoscopic procedures.

Steatosis was found more often with HCV monoinfection than with HCV/HIV and more commonly detected with imaging than with biopsy.

HCV infection was found to be an independent and significant risk factor for death in patients with chronic kidney disease on maintenance dialysis.

A gene linked to risk for steatosis predicted likelihood of patients with sustained virologic response recovering from decompensated HCV cirrhosis.

Sustained virologic response rates were high among HCV/HIV coinfected patients with early treatment discontinuation the only factor associated with lower SVR rate.

Complete Response Letter calls for root cause analysis and data from planed registration batches.

Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

Investigators recognize sustained virologic response to DAAs for hepatitis C infection as valid clinical endpoint of treatment, but question how it relates to long-term health.

After demonstrating success of direct-acting antivirals for HCV in cancer patients, investigators call for their eligibility to participate in chemo trials.

Scientists at the Task Force for Global Health describe what is needed to eliminate HBV and HCV as public health threats.

Models indicate that a vaccine with just 30% efficacy would significantly reduce HCV transmission if provided to persons at high risk of infection from injecting drugs.

First prospective study of direct-acting antiviral treatment of HCV in cancer patients finds that it is safe, efficacious, and that it can open options for chemotherapy.

Researchers calculate universal HCV screening of pregnant women would be cost-effective in the US, including in states with low HCV prevalence.

Analysis of multiple studies demonstrates glecaprevir/pibrentasvir pangenotypic HCV efficacy despite concurrent gastric acid-reducing drugs.

The new guideline centers on the overall diagnosis, management, and clinical treatment of the chronic inflammatory disease.

Direct-acting antiviral treatment of HCV prior to liver transplant does not increase pre-transplant liver cancer progression or post-transplant recurrence.

The first prospective, longitudinal study of direct-acting antivirals for HCV finds that treatment reduces risks of all-cause mortality and liver cancer.

A novel method to inactivate HCV in donor lungs could allow additional transplants without post-transplant antiviral treatment.

Successful HCV treatment with direct-acting antivirals provides long-term efficacy in resolving HCV-associated cryoglobulinemia vasculitis.

Sustained virologic response was achieved regardless of the hepatitis C genotype.